NASDAQ · TNGX
Tango Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TNGX: Nov 3, 2026
Tango Therapeutics, Inc. is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.34. The reported EPS for the same quarter last year was $0.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.34 | $-0.30 | $-0.41 | 7 |
| Dec 2026 | $-0.36 | $-0.31 | $-0.44 | 7 |
| Mar 2027 | $-0.38 | $-0.35 | $-0.47 | 5 |
| Jun 2027 | $-0.41 | $-0.37 | $-0.52 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews · Fintel- Zacks · Oct 26, 10:41 AM EDTTNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataTango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
- MarketBeat · Oct 23, 12:06 PM EDTTango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response RateTango Therapeutics (NASDAQ:TNGX) said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC. The
- RTTNews · Oct 23, 9:23 AM EDTTango Therapeutics Maps 2027 Phase 3 Trial After Promising Cancer Data;Stock Down In Pre-Market(RTTNews) – Tango Therapeutics, Inc. (TNGX) reported updated Phase 1/2 results showing an 82% objective response rate for its investigational drug vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitor daraxonrasib in patients with previously treated MTAP-delete
- RTTNews · Oct 23, 9:12 AM EDTTango Therapeutics Reports 82% Response Rate In Pancreatic Cancer Trial(RTTNews) – Tango Therapeutics (TNGX) reported updated Phase 1/2 results for vopimetostat plus daraxonrasib in patients with previously treated MTAP-deleted, RAS-mutant pancreatic cancer.
- Fintel · Oct 23, 7:43 AM EDTTango Therapeutics, Inc. Announces Phase 1/2 Vopimetostat Trial Results and 14% Workforce ReductionTango Therapeutics, Inc. announced updated results from its ongoing Phase 1/2 clinical trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. As of the August 20, 2026 data cutoff date, updated data from the study demonstrated an 82%
- Zacks · Sep 10, 11:30 AM EDTWhy Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Aug 27, 1:00 PM EDTRVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic CancerRasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.
- Zacks · Aug 12, 10:46 AM EDTTNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher ExpensesTango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
- RTTNews · Aug 11, 10:30 AM EDTTango Therapeutics Q2 Net Loss Expands; Vopimetostat Phase 1/2 Readouts Set For H2 2026; Stock Down(RTTNews) – Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, reported financial results for the second quarter of 2026 reflecting a wider net loss. In addition, the company provided an update on the near-term milestones for its investigational pipeline.
- RTTNews · Aug 11, 10:30 AM EDTTango Therapeutics Net Loss Expands; Vopimetostat Phase 1/2 Readouts Set For H2 2026; Stock Down(RTTNews) – Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, reported financial results for the second quarter of 2026 reflecting a wider net loss. In addition, the company provided an update on the near-term milestones for its investigational pipeline.
- Zacks · Aug 3, 10:34 AM EDT4 Biotech Stocks Likely to Outpace Q2 Earnings EstimatesMedical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
- Zacks · Jul 23, 1:10 PM EDTFDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic CancerRevolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Tango Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.